Definium Therapeutics, Inc.
DFTXDefinium Therapeutics, Inc. in brief
Definium Therapeutics, Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. Its market value was $5.2 B on 29 October 2026, which makes it the 3,474th largest listed company in the world and the 1,031st largest in the USA on this site. It employs about 105 people. Its shares trade under the symbol DFTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Definium Therapeutics, Inc.
We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our lead product candidates.
From the company's annual report filed with the US SEC: read the report
Definium Therapeutics, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2026
- ✎Renamed Definium Therapeutics, Inc.Formerly Mind Medicine (MindMed) Inc..
Events of Definium Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #1,097 (Oct 2026) · #1,032 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 15.7×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -55.3%
- Liabilities / assets
- 24.5%
- Net debt
- $-217M
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-166M | $-184M | — |
| Dec 2024 | — | — | $-104M | $-109M | — |
| Dec 2023 | — | — | $-94M | $-96M | — |
| Dec 2022 | — | — | $-66M | $-57M | — |
| Dec 2021 | — | — | $-94M | $-93M | — |
| Dec 2020 | — | — | $-33M | $-34M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-132M | — | — | $-2.06 | — |
| Dec 2024 | $-79M | — | — | $-1.54 | — |
| Dec 2023 | $-64M | — | — | $-2.44 | — |
| Dec 2022 | $-50M | — | — | $-1.84 | — |
| Dec 2021 | $-46M | — | — | $-3.40 | — |
| Dec 2020 | $-24M | — | — | $-0.13 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-51M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations
- Sep 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 8, 20268-KCurrent reportOther events
- Aug 12, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 24, 20268-KCurrent reportMaterial agreement · Other events
- Jun 22, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 19, 20268-KCurrent reportOther events
- May 12, 20268-KCurrent reportOther events
Official filings of Definium Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-166 M
- Net income
- $-184 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $440 M
- Total liabilities
- $108 M
- Total equity
- $332 M
As of December-2025
Top 100 institutional investors in Definium Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 11,772,595 | +539,761 (+4.81%) | 8.60% | $448 M | Nov 13, 2026 |
| 2 | FMR LLC | 9,082,203 | +4,329,282 (+91.09%) | 6.63% | $346 M | Nov 10, 2026 |
| 3 | Capital World Investors | 8,255,584 | +2,887,861 (+53.80%) | 6.03% | $314 M | Nov 12, 2026 |
| 4 | Janus Henderson Group Ltd. | 7,196,316 | — | 5.26% | $274 M | Nov 16, 2026 |
| 5 | Avoro Capital Advisors LLC | 7,050,000 | -138,888 (-1.93%) | 5.15% | $268 M | Nov 16, 2026 |
| 6 | Driehaus Capital Management LLC | 6,788,022 | -57,254 (-0.84%) | 4.96% | $258 M | Nov 16, 2026 |
| 7 | Price T Rowe Associates Inc /MD/ | 4,366,200 | -285,832 (-6.14%) | 3.19% | $166 M | Nov 16, 2026 |
| 8 | Wellington Management Group LLP | 3,671,887 | +722,153 (+24.48%) | 2.68% | $140 M | Nov 16, 2026 |
| 9 | Geode Capital Management, LLC | 3,644,857 | +44 (0.00%) | 2.66% | $139 M | Nov 6, 2026 |
| 10 | State Street Corp | 3,301,116 | +235,726 (+7.69%) | 2.41% | $126 M | Nov 12, 2026 |
| 11 | Capital International Investors | 2,980,623 | +17,213 (+0.58%) | 2.18% | $113 M | Nov 12, 2026 |
| 12 | Octagon Capital Advisors LP | 2,511,000 | -439,000 (-14.88%) | 1.83% | $96 M | Nov 16, 2026 |
| 13 | Alliancebernstein L.P. | 1,938,303 | +135,016 (+7.49%) | 1.42% | $74 M | Nov 16, 2026 |
| 14 | Goldman Sachs Group Inc | 1,935,743 | +134,891 (+7.49%) | 1.41% | $74 M | Nov 16, 2026 |
| 15 | Vanguard Portfolio Management LLC | 1,655,506 | +7,080 (+0.43%) | 1.21% | $63 M | Nov 13, 2026 |
| 16 | Vanguard Capital Management LLC | 1,618,507 | +132,053 (+8.88%) | 1.18% | $62 M | Nov 13, 2026 |
| 17 | Adage Capital Partners GP, L.L.C. | 1,250,000 | +250,000 (+25.00%) | 0.91% | $48 M | Nov 16, 2026 |
| 18 | Charles Schwab Investment Management Inc | 1,189,322 | +105,746 (+9.76%) | 0.87% | $45 M | Nov 16, 2026 |
| 19 | Northern Trust Corp | 1,183,557 | +14,319 (+1.22%) | 0.86% | $45 M | Nov 16, 2026 |
| 20 | Ameriprise Financial Inc | 1,080,929 | -67,434 (-5.87%) | 0.79% | $41 M | Nov 16, 2026 |
| 21 | Woodline Partners LP | 1,003,797 | +156 (+0.02%) | 0.73% | $38 M | Nov 16, 2026 |
| 22 | Deep Track Capital, LP | 1,000,000 | -1,750,000 (-63.64%) | 0.73% | $38 M | Nov 16, 2026 |
| 23 | Lord, Abbett & Co. LLC | 958,635 | New | 0.70% | $36 M | Nov 13, 2026 |
| 24 | UBS Group AG | 928,669 | +429,202 (+85.93%) | 0.68% | $35 M | Nov 10, 2026 |
| 25 | Ensign Peak Advisors, Inc | 913,732 | +447,626 (+96.04%) | 0.67% | $35 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Bank of New York Mellon Corp | 850,275 | +73,004 (+9.39%) | 0.62% | $32 M | Nov 5, 2026 |
| 27 | Vanguard Fiduciary Trust Co | 849,295 | +21,602 (+2.61%) | 0.62% | $32 M | Nov 13, 2026 |
| 28 | Bamco Inc /ny/ | 844,732 | +324,624 (+62.41%) | 0.62% | $32 M | Nov 16, 2026 |
| 29 | Invesco Ltd. | 821,607 | +730,269 (+799.52%) | 0.60% | $31 M | Nov 12, 2026 |
| 30 | Neuberger Berman Group LLC | 794,053 | +106,514 (+15.49%) | 0.58% | $30 M | Nov 13, 2026 |
| 31 | Polar Capital Holdings Plc | 775,961 | -1,292 (-0.17%) | 0.57% | $30 M | Nov 16, 2026 |
| 32 | AWM Investment Company, Inc. | 764,800 | -20,000 (-2.55%) | 0.56% | $29 M | Nov 13, 2026 |
| 33 | Barclays PLC | 761,867 | +711,571 (+1414.77%) | 0.56% | $29 M | Nov 6, 2026 |
| 34 | Commodore Capital LP | 700,000 | -1,300,000 (-65.00%) | 0.51% | $27 M | Nov 16, 2026 |
| 35 | Nuveen, LLC | 685,539 | -419,775 (-37.98%) | 0.50% | $26 M | Nov 10, 2026 |
| 36 | Morgan Stanley | 684,735 | +229,823 (+50.52%) | 0.50% | $26 M | Nov 13, 2026 |
| 37 | Boxer Capital Management, LLC | 683,615 | -314,885 (-31.54%) | 0.50% | $26 M | Nov 16, 2026 |
| 38 | Qube Research & Technologies Ltd | 668,876 | -14,025 (-2.05%) | 0.49% | $25 M | Nov 13, 2026 |
| 39 | Eventide Asset Management, LLC | 662,459 | -47,541 (-6.70%) | 0.48% | $25 M | Nov 13, 2026 |
| 40 | Franklin Templeton Inc | 580,361 | +94,142 (+19.36%) | 0.42% | $22 M | Nov 12, 2026 |
| 41 | Balyasny Asset Management L.P. | 549,443 | -348,215 (-38.79%) | 0.40% | $21 M | Nov 16, 2026 |
| 42 | Bank Of America Corp /de/ | 518,512 | +353,937 (+215.06%) | 0.38% | $20 M | Nov 16, 2026 |
| 43 | Candriam S.C.A. | 515,277 | -99,148 (-16.14%) | 0.38% | $20 M | Nov 3, 2026 |
| 44 | Great Point Partners LLC | 508,735 | +83,735 (+19.70%) | 0.37% | $19 M | Nov 16, 2026 |
| 45 | Integral Health Asset Management, LLC | 500,000 | -50,000 (-9.09%) | 0.37% | $19 M | Nov 16, 2026 |
| 46 | Catalio Capital Management, LP | 497,964 | -64,708 (-11.50%) | 0.36% | $19 M | Nov 16, 2026 |
| 47 | Marshall Wace, LLP | 491,029 | -807,917 (-62.20%) | 0.36% | $19 M | Nov 13, 2026 |
| 48 | Seven Grand Managers, LLC | 475,000 | +250,000 (+111.11%) | 0.35% | $18 M | Nov 16, 2026 |
| 49 | ArrowMark Colorado Holdings LLC | 469,831 | -94,238 (-16.71%) | 0.34% | $18 M | Nov 16, 2026 |
| 50 | Orbimed Advisors LLC | 443,900 | +78,500 (+21.48%) | 0.32% | $17 M | Nov 16, 2026 |
| 51 | Assetmark, Inc | 399,964 | +3,422 (+0.86%) | 0.29% | $15 M | Oct 21, 2026 |
| 52 | Patient Square Capital LP | 385,000 | New | 0.28% | $15 M | Nov 10, 2026 |
| 53 | Susquehanna International Group, LLP | 367,147 | +326,193 (+796.49%) | 0.27% | $14 M | Nov 16, 2026 |
| 54 | Logos Global Management LP | 350,000 | +270,000 (+337.50%) | 0.26% | $13 M | Nov 16, 2026 |
| 55 | Silverarc Capital Management, LLC | 345,946 | -54,054 (-13.51%) | 0.25% | $13 M | Nov 12, 2026 |
| 56 | Squadron Capital Management LLC | 340,000 | +255,000 (+300.00%) | 0.25% | $13 M | Nov 16, 2026 |
| 57 | Sofinnova Investments, Inc. | 339,018 | +83,115 (+32.48%) | 0.25% | $13 M | Nov 16, 2026 |
| 58 | Jpmorgan Chase & Co | 337,191 | +71,236 (+26.78%) | 0.25% | $13 M | Nov 12, 2026 |
| 59 | PFM Health Sciences, LP | 335,101 | +86,081 (+34.57%) | 0.24% | $13 M | Nov 16, 2026 |
| 60 | Russell Investments Group, Ltd. | 331,702 | +178,225 (+116.12%) | 0.24% | $13 M | Nov 6, 2026 |
| 61 | Royal Bank Of Canada | 312,693 | +212,630 (+212.50%) | 0.23% | $12 M | Nov 16, 2026 |
| 62 | Tetragon Partners GP Ltd | 310,892 | +23,902 (+8.33%) | 0.23% | $12 M | Nov 16, 2026 |
| 63 | Cormorant Asset Management, LP | 275,000 | -125,000 (-31.25%) | 0.20% | $10 M | Nov 16, 2026 |
| 64 | Royce & Associates LP | 250,547 | +41,996 (+20.14%) | 0.18% | $10 M | Nov 9, 2026 |
| 65 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 240,266 | +29,083 (+13.77%) | 0.18% | $9 M | Nov 16, 2026 |
| 66 | Swiss National Bank | 228,100 | +6,900 (+3.12%) | 0.17% | $9 M | Nov 12, 2026 |
| 67 | Fred Alger Management, LLC | 226,345 | +101,089 (+80.71%) | 0.17% | $9 M | Nov 16, 2026 |
| 68 | Two Sigma Investments, LP | 225,938 | -695,880 (-75.49%) | 0.17% | $9 M | Nov 16, 2026 |
| 69 | Keystone Investors Pte LTD | 221,080 | +125,980 (+132.47%) | 0.16% | $8 M | Nov 16, 2026 |
| 70 | First Turn Management, LLC | 216,531 | New | 0.16% | $8 M | Nov 16, 2026 |
| 71 | Schroder Investment Management Group | 209,694 | New | 0.15% | $8 M | Nov 16, 2026 |
| 72 | SEB Asset Management AB | 208,254 | 0 (0.00%) | 0.15% | $8 M | Nov 4, 2026 |
| 73 | Aberdeen Group plc | 192,415 | +17,415 (+9.95%) | 0.14% | $7 M | Nov 10, 2026 |
| 74 | AQR Capital Management LLC | 182,923 | +48,771 (+36.36%) | 0.13% | $7 M | Nov 16, 2026 |
| 75 | HSBC Holdings PLC | 182,786 | +65,304 (+55.59%) | 0.13% | $7 M | Nov 16, 2026 |
| 76 | Alps Advisors Inc | 178,006 | +67,618 (+61.25%) | 0.13% | $7 M | Nov 3, 2026 |
| 77 | Superstring Capital Management LP | 176,561 | -11,721 (-6.23%) | 0.13% | $7 M | Nov 16, 2026 |
| 78 | Voya Investment Management LLC | 166,443 | +71,277 (+74.90%) | 0.12% | $6 M | Nov 10, 2026 |
| 79 | AdvisorShares Investments LLC | 161,608 | +40,227 (+33.14%) | 0.12% | $6 M | Nov 9, 2026 |
| 80 | Rhumbline Advisers | 160,569 | +2,473 (+1.56%) | 0.12% | $6 M | Nov 10, 2026 |
| 81 | D. E. Shaw & Co., Inc. | 159,305 | -156,105 (-49.49%) | 0.12% | $6 M | Nov 16, 2026 |
| 82 | Rock Springs Capital Management LP | 154,188 | +11,001 (+7.68%) | 0.11% | $6 M | Nov 16, 2026 |
| 83 | Moody Aldrich Partners LLC | 148,870 | +97,845 (+191.76%) | 0.11% | $6 M | Oct 27, 2026 |
| 84 | Clearbridge Investments, LLC | 148,781 | New | 0.11% | $6 M | Nov 12, 2026 |
| 85 | Deutsche Bank AG\ | 144,657 | +1,710 (+1.20%) | 0.11% | $6 M | Nov 6, 2026 |
| 86 | Tri Locum Partners LP | 144,406 | -18,590 (-11.41%) | 0.11% | $5 M | Nov 16, 2026 |
| 87 | Peregrine Capital Management LLC | 142,129 | New | 0.10% | $5 M | Nov 9, 2026 |
| 88 | Van Eck Associates Corp | 132,348 | New | 0.10% | $5 M | Nov 13, 2026 |
| 89 | California State Teachers Retirement System | 130,576 | +2,230 (+1.74%) | 0.10% | $5 M | Nov 13, 2026 |
| 90 | Atom Investors LP | 125,807 | +76,371 (+154.48%) | 0.09% | $5 M | Nov 16, 2026 |
| 91 | VANGUARD ASSET MANAGEMENT, Ltd | 120,728 | +42,124 (+53.59%) | 0.09% | $5 M | Nov 13, 2026 |
| 92 | TD Asset Management Inc | 118,060 | -91,400 (-43.64%) | 0.09% | $4 M | Nov 13, 2026 |
| 93 | HighVista Strategies LLC | 109,086 | -133,798 (-55.09%) | 0.08% | $4 M | Nov 13, 2026 |
| 94 | Seven Fleet Capital Management LP | 108,647 | -40,000 (-26.91%) | 0.08% | $4 M | Nov 16, 2026 |
| 95 | Verition Fund Management LLC | 107,737 | New | 0.08% | $4 M | Nov 13, 2026 |
| 96 | Nicholas Investment Partners, LP | 105,175 | New | 0.08% | $4 M | Nov 16, 2026 |
| 97 | Manufacturers Life Insurance Company, The | 104,035 | -42,333 (-28.92%) | 0.08% | $4 M | Nov 13, 2026 |
| 98 | Informed Momentum Co LLC | 103,484 | -17,444 (-14.43%) | 0.08% | $4 M | Nov 16, 2026 |
| 99 | Data Collective IV GP, LLC | 100,350 | 0 (0.00%) | 0.07% | $4 M | Nov 16, 2026 |
| 100 | Brevan Howard Capital Management LP | 97,275 | -59,537 (-37.97%) | 0.07% | $4 M | Nov 16, 2026 |
Mutual funds holding Definium Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc | 7.69 M | $362 M | 5.6% | 0.38% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.35 M | $157 M | 2.4% | 0.19% | +39% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.49 M | $70 M | 1.1% | 0.07% | +36% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.42 M | $62 M | 1.0% | 0.18% | +46% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 1.29 M | $61 M | 0.94% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 1.19 M | $56 M | 0.87% | 0.36% | +373% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 1.14 M | $54 M | 0.83% | 0.36% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 743,400 | $35 M | 0.54% | 0.38% | +5.7% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 728,490 | $34 M | 0.53% | 0.35% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 779,396 | $34 M | 0.57% | 0.39% | −4.6% | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund | 710,241 | $33 M | 0.52% | 0.58% | new | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 710,000 | $33 M | 0.52% | 1.9% | +3.5% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care FundWellington Management Company LLP | 740,600 | $32 M | 0.54% | 0.08% | new | Jul 31, 2026 |
| 🇺🇸 Driehaus Small Cap Growth FundDriehaus Capital Management LLC | 595,284 | $28 M | 0.43% | 1.7% | +28% | Jun 30, 2026 |
| 🇺🇸 Lord Abbett Developing Growth Fund IncLord, Abbett & Co. LLC | 538,017 | $23 M | 0.39% | 1.1% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 528,300 | $23 M | 0.39% | 0.31% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 511,828 | $22 M | 0.37% | 0.10% | −9.0% | Jul 31, 2026 |
| 🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P. | 439,375 | $21 M | 0.32% | 0.66% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Blue Chip Growth FundFidelity Management & Research Company LLC | 449,300 | $20 M | 0.33% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 409,890 | $18 M | 0.30% | 0.39% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 373,412 | $18 M | 0.27% | 0.30% | +217% | Jun 30, 2026 |
| 🇺🇸 Columbia Acorn FundColumbia Management Investment Advisers, LLC | 366,447 | $17 M | 0.27% | 0.62% | −28% | Jun 30, 2026 |
| 🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P. | 356,881 | $17 M | 0.26% | 0.58% | new | Jun 30, 2026 |
| 🇺🇸 Baron Discovery FundBAMCO, Inc. | 356,396 | $17 M | 0.26% | 0.92% | new | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 354,369 | $17 M | 0.26% | 0.15% | +5956% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Pharmaceuticals ETFBlackRock Fund Advisors | 336,035 | $16 M | 0.25% | 1.4% | +22% | Jun 30, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 348,339 | $15 M | 0.25% | 0.61% | new | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 341,580 | $15 M | 0.25% | 0.37% | −25% | Jul 31, 2026 |
| 🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC | 308,458 | $15 M | 0.23% | 2.4% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 316,210 | $14 M | 0.23% | 0.18% | +46% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Pharmaceuticals ETFSSGA Funds Management, Inc. | 281,317 | $13 M | 0.21% | 3.1% | −11% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 303,300 | $13 M | 0.22% | 0.28% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC | 300,955 | $13 M | 0.22% | 0.31% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 509,162 | $12 M | 0.37% | 0.03% | −9.2% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 505,777 | $12 M | 0.37% | 0.07% | +8.5% | May 31, 2026 |
| 🇺🇸 Meridian Growth FundArrowMark Colorado Holdings, LLC | 254,159 | $12 M | 0.19% | 2.2% | −2.7% | Jun 30, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 473,075 | $11 M | 0.35% | 0.05% | −1.6% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 239,678 | $11 M | 0.18% | 0.19% | +50% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 238,664 | $11 M | 0.17% | <0.01% | +95% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 257,424 | $11 M | 0.19% | 0.45% | +13371% | Jul 31, 2026 |
| 🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC | 220,767 | $10 M | 0.16% | 0.41% | +98% | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World FundCapital Research and Management Company | 209,315 | $10 M | 0.15% | 0.38% | new | Jun 30, 2026 |
| 🇸🇪 SEB LäkemedelsfondSEB Funds AB | 208,254 | $10 M | 0.15% | 0.54% | new | Jun 30, 2026 |
| 🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I | 193,657 | $9 M | 0.14% | 1.1% | −12% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 183,332 | $9 M | 0.13% | 0.38% | +567% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 155,099 | $7 M | 0.11% | <0.01% | +2.5% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 166,814 | $7 M | 0.12% | 0.18% | +42% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Growth PortfolioPacific Life Fund Advisors LLC | 151,618 | $7 M | 0.11% | 1.2% | +48% | Jun 30, 2026 |
| 🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP | 151,000 | $7 M | 0.11% | 3.0% | +2.0% | Jun 30, 2026 |
| 🇺🇸 Emerald Growth FundRBB Fund, Inc. | 161,989 | $7 M | 0.12% | 0.48% | — | Jul 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 161,200 | $7 M | 0.12% | 0.32% | −37% | Jul 31, 2026 |
| 🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc. | 144,089 | $7 M | 0.11% | 0.32% | +11% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 139,659 | $7 M | 0.10% | 0.17% | +38% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 241,171 | $6 M | 0.18% | 0.03% | +0.2% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 121,945 | $6 M | 0.09% | 0.37% | +422% | Jun 30, 2026 |
| 🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC | 115,671 | $5 M | 0.08% | 2.0% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 120,090 | $5 M | 0.09% | <0.01% | +89% | Jul 31, 2026 |
| 🇺🇸 Small Cap Growth Stock PortfolioMason Street Advisors, LLC | 97,500 | $5 M | 0.07% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Select Pharmaceuticals PortfolioFidelity Management & Research Company LLC | 188,000 | $5 M | 0.14% | 0.30% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Blue Chip Growth ETFFidelity Management & Research Company LLC | 103,206 | $4 M | 0.08% | 0.06% | new | Jul 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 95,455 | $4 M | 0.07% | 0.33% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 185,050 | $4 M | 0.14% | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 89,800 | $4 M | 0.07% | 0.19% | +48% | Jun 30, 2026 |
| 🇺🇸 Fidelity Blue Chip Growth K6 FundFidelity Management & Research Company LLC | 93,300 | $4 M | 0.07% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Nuveen ESG Small-Cap ETFNuveen Fund Advisors, LLC | 90,473 | $4 M | 0.07% | 0.31% | +8.1% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 81,159 | $4 M | 0.06% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 81,141 | $4 M | 0.06% | 0.34% | new | Jun 30, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 86,980 | $4 M | 0.06% | 0.33% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P. | 79,711 | $4 M | 0.06% | 0.44% | new | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 79,545 | $4 M | 0.06% | 0.54% | new | Jun 30, 2026 |
| 🇺🇸 Adara Smaller Companies FundRBB Fund, Inc. | 150,124 | $4 M | 0.11% | 0.44% | no change | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 77,130 | $4 M | 0.06% | 0.19% | +46% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 149,873 | $4 M | 0.11% | <0.01% | +2.5% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 76,035 | $4 M | 0.06% | 0.27% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 79,611 | $3 M | 0.06% | <0.01% | +28% | Jul 31, 2026 |
| 🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP | 72,500 | $3 M | 0.05% | 0.13% | −16% | Jun 30, 2026 |
| 🇺🇸 Hartford Small Cap Growth HLS FundHartford Funds Management Company, LLC | 72,200 | $3 M | 0.05% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Columbia Variable Portfolio - Acorn FundColumbia Management Investment Advisers, LLC | 71,158 | $3 M | 0.05% | 0.62% | −28% | Jun 30, 2026 |
| 🇺🇸 Column Small Cap Select FundTrust for Professional Managers | 136,454 | $3 M | 0.10% | 0.17% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Blue Chip Growth FundFidelity Management & Research Company LLC | 74,400 | $3 M | 0.05% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC | 133,760 | $3 M | 0.10% | 0.47% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 65,803 | $3 M | 0.05% | 0.19% | +46% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Growth FundGoldman Sachs Asset Management, L.P. | 127,905 | $3 M | 0.09% | 0.67% | +34% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 70,287 | $3 M | 0.05% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series | 68,629 | $3 M | 0.05% | 0.36% | new | Jul 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 62,307 | $3 M | 0.05% | 0.18% | +46% | Jul 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 55,953 | $3 M | 0.04% | 0.16% | −85% | Jun 30, 2026 |
| 🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC | 57,703 | $3 M | 0.04% | 0.49% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC | 56,500 | $2 M | 0.04% | 0.18% | new | Jul 31, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 51,914 | $2 M | 0.04% | 0.34% | new | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Small Cap Value FundGoldman Sachs Asset Management, L.P. | 97,359 | $2 M | 0.07% | 0.25% | new | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Growth Opportunities FundNuveen Fund Advisors, LLC | 52,699 | $2 M | 0.04% | 0.87% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 52,257 | $2 M | 0.04% | 0.07% | +41% | Jul 31, 2026 |
| 🇺🇸 Variable Portfolio - Partners Small Cap Growth FundColumbia Management Investment Advisers, LLC | 46,031 | $2 M | 0.03% | 0.57% | +22% | Jun 30, 2026 |
| 🇺🇸 The Hartford Healthcare FundHartford Funds Management Company, LLC | 49,500 | $2 M | 0.04% | 0.28% | new | Jul 31, 2026 |
| 🇺🇸 The Hartford Small Company FundHartford Funds Management Company, LLC | 48,700 | $2 M | 0.04% | 0.31% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 86,461 | $2 M | 0.06% | 0.11% | +44% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 47,936 | $2 M | 0.04% | 0.08% | +39% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 43,003 | $2 M | 0.03% | 0.19% | +39% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 81,265 | $2 M | 0.06% | 0.03% | new | May 29, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Definium Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Robert BarrowChief Executive Officer, Director | Sell10b5-1 plan | -31,550 | $36.57 | $1.2 M | 2.21 M | Form 4 |
| filed | Daniel KarlinChief Medical Officer, Director | Sell10b5-1 plan | -10,853 | $36.57 | $397 K | 792,846 | Form 4 |
| filed | Mark SullivanChief Legal Officer | Sell10b5-1 plan | -14,051 | $36.57 | $514 K | 494,228 | Form 4 |
| filed | Brandi RobertsChief Financial Officer | Sell10b5-1 plan | -3,377 | $36.57 | $123 K | 394,528 | Form 4 |
| filed | Matthew T. WileyChief Commercial Officer | Sell10b5-1 plan | -3,097 | $36.57 | $113 K | 359,036 | Form 4 |
| filed | Andreas KrebsDirector | Option exercise | +1,629 | $35.52 | $58 K | 21,402 | Form 4 |
| filed | Carol A. ValloneDirector | Option exercise | +1,086 | $35.52 | $39 K | 22,296 | Form 4 |
| filed | Brandi RobertsChief Financial Officer | Grant or award | +125,000 | — | — | 397,905 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Definium Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-09-14 10:55 UTC, code T3, resumed 11:30 UTC
- 2026-08-12 10:55 UTC, code T3, resumed 11:30 UTC
Fails to deliver
- : 504 shares at $38.10
- : 9,851 shares at $37.08
- : 45 shares at $35.68
- : 4,643 shares at $35.67
- : 265 shares at $32.10
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Definium Therapeutics, Inc. scorecard#
Passes 3 of the 14 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median15.7×Price to book 15.7× against Healthcare's median of 3.1×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.06 vs -1.54Diluted EPS -2.06 in fiscal 2025 against -1.54 the year before (report's currency).
- ✗Net income higher than five years earlier-$184 M-$184 M in fiscal 2025 against -$34 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$184 MNet income -$184 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-64.1%-64.1% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.29 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.12 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $217 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-30.4×Operating income -30.4 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year26.8%Diluted shares up 26.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Definium Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 118+80.2%— | 65+25.3%— | 52+44.1%— | 36+4.0%— | 35+86.7%— | 19—— | |
| General and administrative | 49+26.0%— | 39−7.5%— | 42+38.4%— | 30−48.9%— | 59+310%— | 14—— | |
| Operating expenses | 166+60.0%— | 104+10.7%— | 94+41.5%— | 66−29.3%— | 94+184%— | 33—— | |
| Operating income | −166—— | −104—— | −94—— | −66—— | −94—— | −33—— | |
| Interest and finance income | 11−5.2%— | 12+107%— | 5.6—— | — | — | — | |
| Interest expense and finance costs | 5.5+140%— | 2.3+148%— | 0.9r0.7—— | — | — | — | |
| Net interest income | — | — | 4.7+212%— | 1.5—— | −0.4—— | −0.2—— | |
| Other non-operating income (expense) | −17—— | −4.8—— | −1.9−120%— | 9.5—— | −0.3—— | −0.9—— | |
| Income before tax | −184—— | −109—— | −96—— | −57—— | −94—— | −34—— | |
| Income tax | 0—— | — | — | — | −1.2—— | — | |
| Net income including minority interests | −184—— | −109—— | −96—— | −57—— | −93—— | −34—— | |
| Net income attributable to shareholders | −184—— | −109—— | −96—— | −57—— | −93—— | −34—— | |
| Earnings per share, basic | -2.06—— | -1.54—— | -2.44—— | -1.84—— | -3.40r-0.23—— | -0.13—— | |
| Earnings per share, diluted | -2.06—— | -1.54—— | -2.44—— | -1.84—— | -3.40r-0.23—— | -0.13—— | |
| Shares, weighted average (basic) | 89+26.8%— | 70+79.9%— | 39+26.9%— | 31+12.7%— | 27—— | — | |
| Shares, weighted average (diluted) | 89+26.8%— | 70+79.9%— | 39+26.9%— | 31+12.7%— | 27r411−89.7%— | 266—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 258−5.8%58.6% | 274+175%90.6% | 100−29.9%80.1% | 142+6.4%83.6% | 134+66.7%81.4% | 80—98.3% | |
| Short-term investments | 154—34.9% | 0—0.0% | — | — | — | — | |
| Other current assets | 7.7−1.9%1.8% | 7.9+89.0%2.6% | 4.2+6.5%3.3% | 3.9+6.4%2.3% | 3.7+158%2.2% | 1.4—1.7% | |
| Current assets | 419+48.9%95.3% | 282+171%93.2% | 104−28.9%83.4% | 146+6.4%85.9% | 137+68.3%83.7% | 82—100% | |
| Goodwill | 200.0%4.5% | 200.0%6.6% | 200.0%16.0% | 200.0%11.7% | 20—12.1% | 0—0.0% | |
| Other intangible assets | — | 0−100%0.0% | 0.5−85.7%0.4% | 3.7−46.3%2.2% | 6.9—4.2% | — | |
| Long-term investments | — | 0—0.0% | — | — | — | — | |
| Total assets | 440+45.7%100% | 302+143%100% | 125−26.7%100% | 170+3.7%100% | 164+101%100% | 82—100% | |
| Accounts payable | 5.3+166%1.2% | 2.0−51.4%0.7% | 4.1+95.9%3.3% | 2.1−49.5%1.2% | 4.2+107%2.5% | 2.0—2.5% | |
| Current liabilities | 67+71.7%15.2% | 39+20.5%12.9% | 32+80.2%25.9% | 18+71.9%10.5% | 10+246%6.3% | 3.0—3.7% | |
| Long-term debt | 41+85.7%9.2% | 22+54.7%7.2% | 14—11.3% | — | — | — | |
| Total liabilities | 108+77.5%24.5% | 61+30.8%20.1% | 46+143%37.3% | 19+54.6%11.2% | 12+118%7.5% | 5.7—6.9% | |
| Retained earnings | −583—−132% | −399—−132% | −290—−233% | −194—−114% | −138—−83.9% | −45—−54.8% | |
| Shareholders' equity | 332+37.6%75.5% | 241+209%79.9% | 78−48.2%62.7% | 151−0.5%88.8% | 152+99.9%92.5% | 76—93.1% | |
| Total liabilities and equity | 440+45.7%100% | 302+143%100% | 125−26.7%100% | 170+3.7%100% | 164+101%100% | 82—100% | |
| Shares outstanding | 99+31.5%— | 75+82.7%— | 41+8.2%— | 38+35.0%— | 28r422—— | — | |
| Cash-flow statement | |||||||
| Share-based compensation | 20+18.8%— | 17+11.4%— | 15r15+10.8%— | 14−67.9%— | 43+477%— | 7.4—— | |
| Cash from operating activities | −132—— | −79—— | −64—— | −50—— | −46—— | −24—— | |
| Acquisitions, net of cash acquired | — | — | — | — | −0.3—— | — | |
| Cash from investing activities | −152—— | 0—— | — | — | −0.3—— | — | |
| Shares issued | 0−100%— | 1.0−86.9%— | 7.5−82.2%— | 42−48.4%— | 82+13.8%— | 72—— | |
| Cash from financing activities | 267+5.6%— | 253+1059%— | 22−63.0%— | 59−40.2%— | 99+2.2%— | 97—— | |
| Change in cash | −16−109%— | 174—— | −42−593%— | 8.6−83.9%— | 53−27.2%— | 73—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 170+60.3%— | 46+48.9%— | 49+63.3%— | 41+77.6%— | 34*+54.1%— | 31+80.2%— | 30+104%— | 23+99.5%— | 22*+88.5%— | 17—— | 15—— | 12—— | 12*—— | |
| General and administrative | 84+86.2%— | 26+77.9%— | 26+138%— | 18+101%— | 14*+31.3%— | 15+93.2%— | 11+13.1%— | 8.8−16.2%— | 11*+0.4%— | 7.6—— | 9.8—— | 10—— | 11*—— | |
| Operating expenses | 254+68.1%— | 72+58.3%— | 75+83.5%— | 59+84.1%— | 48*+46.6%— | 46+84.2%— | 41+67.2%— | 32+44.8%— | 32*+46.2%— | 25—— | 24—— | 22—— | 22*—— | |
| Operating income | −254—— | −72—— | −75—— | −59—— | −48*—— | −46—— | −41—— | −32—— | −32*—— | −25—— | −24—— | −22—— | −22*—— | |
| Interest and finance income | 21+92.4%— | 10+348%— | 3.6+29.3%— | 3.5+42.1%— | 3.5*+6.5%— | 2.3−35.5%— | 2.8−11.0%— | 2.4+46.9%— | 3.3*+144%— | 3.5—— | 3.1—— | 1.7—— | 1.3*—— | |
| Interest expense and finance costs | 4.9+0.5%— | 1.2−9.7%— | 1.2−47.3%— | 1.2+107%— | 1.3*+93.3%— | 1.3+75.2%— | 2.3+402%— | 0.6+38.7%— | 0.7*+49.4%— | 0.7—— | 0.5—— | 0.4—— | 0.4*—— | |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | — | 0.9*—— | |
| Other non-operating income (expense) | −83—— | 21—— | −84—— | −18−303%— | −2.9*—— | −22−294%— | −1.8−110%— | 8.8—— | −2.3*—— | 11—— | 19—— | −32—— | −1.7*—— | |
| Net income including minority interests | −337—— | −51*—— | −159*—— | −77—— | −50*—— | −67*—— | −43*—— | −23—— | −35*—— | −14*—— | −5.9*—— | −54—— | −24*—— | |
| Net income attributable to shareholders | −337—— | −51—— | −159—— | −77—— | −50*—— | −67—— | −43—— | −23—— | −35*—— | −14—— | −5.9—— | −54—— | −24*—— | |
| Earnings per share, basic | — | -0.37—— | -1.44—— | -0.71—— | — | -0.78—— | -0.50—— | -0.27—— | — | -0.18—— | -0.08—— | -1.14—— | — | |
| Earnings per share, diluted | — | -0.46—— | -1.44—— | -0.71—— | — | -0.78—— | -0.50—— | -0.35—— | — | -0.27—— | -0.26—— | -1.14—— | — | |
| Shares, weighted average (basic) | 136+58.3%— | 136+58.3%— | 111+29.7%— | 109+27.9%— | — | 86+10.2%— | 85+18.7%— | 85+77.7%— | — | 78—— | 72—— | 48—— | — | |
| Shares, weighted average (diluted) | 137+59.9%— | 137+59.9%— | 111+29.7%— | 109+24.9%— | — | 86+7.0%— | 85+13.3%— | 87+82.0%— | — | 80—— | 75—— | 48—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 241—22.4% | 241+1108%22.4% | 655+1862%58.9% | 263+217%65.4% | 258−5.8%58.6% | 20−93.2%8.4% | 33−86.3%12.6% | 83−67.2%30.1% | 274+175%90.6% | 295—92.3% | 243—90.7% | 252—91.6% | 100—80.1% | |
| Short-term investments | 806—75.0% | 806+326%75.0% | 429+187%38.5% | 111−14.4%27.6% | 154—34.9% | 189—79.8% | 150—56.4% | 130—47.1% | 0—0.0% | — | — | — | — | |
| Other current assets | 4.9—0.5% | 4.9−27.5%0.5% | 8.2+33.8%0.7% | 7.1−22.9%1.8% | 7.7−1.9%1.8% | 6.8+66.4%2.9% | 6.1+34.7%2.3% | 9.3+195%3.4% | 7.9+89.0%2.6% | 4.1—1.3% | 4.6—1.7% | 3.1—1.1% | 4.2—3.3% | |
| Current assets | 1,052—97.9% | 1,052+387%97.9% | 1,092+477%98.1% | 381+71.7%94.8% | 419+48.9%95.3% | 216−27.9%91.1% | 189−23.6%71.3% | 222−13.2%80.5% | 282+171%93.2% | 299—93.6% | 248—92.4% | 255—92.7% | 104—83.4% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | 0.6—0.2% | — | — | — | — | — | — | |
| Goodwill | 20—1.9% | 200.0%1.9% | 200.0%1.8% | 200.0%5.0% | 200.0%4.5% | 200.0%8.4% | 200.0%7.5% | 200.0%7.2% | 200.0%6.6% | 20—6.2% | 20—7.4% | 20—7.2% | 20—16.0% | |
| Other intangible assets | — | — | — | — | — | — | — | — | 0−100%0.0% | — | — | — | 0.5—0.4% | |
| Long-term investments | — | — | — | — | — | — | 55—20.7% | 33—12.0% | 0—0.0% | — | — | — | — | |
| Total assets | 1,074—100% | 1,074+353%100% | 1,113+320%100% | 401+45.8%100% | 440+45.7%100% | 237−25.9%100% | 265−1.1%100% | 275−0.1%100% | 302+143%100% | 320—100% | 268—100% | 276—100% | 125—100% | |
| Accounts payable | 9.3—0.9% | 9.3+14.3%0.9% | 7.0+65.2%0.6% | 7.1+214%1.8% | 5.3+166%1.2% | 8.1+278%3.4% | 4.2+43.6%1.6% | 2.3−70.1%0.8% | 2.0−51.4%0.7% | 2.1—0.7% | 2.9—1.1% | 7.6—2.8% | 4.1—3.3% | |
| Current liabilities | 68—6.3% | 68+3.5%6.3% | 157+314%14.1% | 81+166%20.2% | 67+71.7%15.2% | 65+96.7%27.6% | 38−9.3%14.3% | 30−53.3%11.1% | 39+20.5%12.9% | 33—10.4% | 42—15.6% | 65—23.7% | 32—25.9% | |
| Long-term debt | 37—3.4% | 37−9.2%3.4% | 36−11.5%3.3% | 41+85.0%10.2% | 41+85.7%9.2% | 40+66.1%17.0% | 41+69.9%15.5% | 22+55.3%8.0% | 22+54.7%7.2% | 24—7.6% | 24—9.0% | 14—5.2% | 14—11.3% | |
| Total liabilities | 106—9.9% | 106−0.1%9.9% | 194+144%17.5% | 122+133%30.5% | 108+77.5%24.5% | 106+84.7%44.9% | 80+20.6%30.1% | 53−33.9%19.1% | 61+30.8%20.1% | 58—18.0% | 66—24.7% | 79—28.8% | 46—37.3% | |
| Retained earnings | −870—−81.0% | −870—−81.0% | −819—−73.6% | −660—−164% | −583—−132% | −532—−225% | −465—−175% | −422—−153% | −399—−132% | −364—−114% | −350—−131% | −345—−125% | −290—−233% | |
| Shareholders' equity | 968—90.1% | 968+641%90.1% | 919+396%82.5% | 279+25.2%69.5% | 332+37.6%75.5% | 131−50.2%55.1% | 185−8.2%69.9% | 223+13.6%80.9% | 241+209%79.9% | 262—82.0% | 202—75.3% | 196—71.2% | 78—62.7% | |
| Total liabilities and equity | 1,074—100% | 1,074+353%100% | 1,113+320%100% | 401+45.8%100% | 440+45.7%100% | 237−25.9%100% | 265−1.1%100% | 275−0.1%100% | 302+143%100% | 320—100% | 268—100% | 276—100% | 125—100% | |
| Shares outstanding | 137—— | 137+78.3%— | 134+77.3%— | 104+37.8%— | 99+31.5%— | 77−5.9%— | 76+5.2%— | 76+6.1%— | 75+82.7%— | 82—— | 72—— | 71—— | 41—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 33+79.7%— | 11+85.3%— | 9.6+83.5%— | 7.1+108%— | 5.6*+41.7%— | 5.8+51.4%— | 5.3−3.3%— | 3.4−7.1%— | 4.0r3.4*+17.5%— | 3.8r3.8—— | 5.4r5.2—— | 3.7r4.5—— | 3.4r3.7*—— | |
| Cash from operating activities | −191—— | −53*—— | −53*—— | −43—— | −43*—— | −30*—— | −30*—— | −29—— | −25*—— | −17*—— | −20*—— | −17—— | −21*—— | |
| Cash from investing activities | −613—— | −373*−2520%— | −317*—— | 42—— | 35*—— | 15*—— | −40*—— | −162—— | 0*—— | 0*—— | 0*—— | 0—— | — | |
| Shares issued | — | — | — | — | 0*—— | 0*—— | — | — | 0*−100%— | 0*—— | — | — | 2.6*—— | |
| Cash from financing activities | 1,025+3967%— | 12*+1457%— | 762*+3779%— | 5.3+430%— | 246*+6358%— | 0.7*−98.9%— | 20*+82.1%— | 1.0−99.4%— | 3.8*+46.8%— | 69*—— | 11*—— | 169—— | 2.6*—— | |
| Change in cash | 221—— | −414*—— | 393*—— | 4.7—— | 238*—— | −13*−126%— | −49*—— | −191−225%— | −22*—— | 52*—— | −9.2*—— | 153—— | −18*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Definium Therapeutics, Inc. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.
Only the headquarters country is on file for Definium Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Definium Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 5 · Material agreement 3 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedResults announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Definium Therapeutics, Inc.#
$370 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues4 reports
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $320 K | $320 K | 7 |
| 2025 | $370 K | $370 K | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “MIND MEDICINE (MINDMED) INC.”, “Definium Therapeutics (fka MIND MEDICINE (MINDMED) INC.)” and “Definium Therapeutics (fka MIND MEDICINE (MINDMED) INC.)”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
Discuss Definium Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 9 November 2026automatic update · Nov 9, 2026
Definium Therapeutics, Inc. announced results on 9 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $51 million.
- Mutual funds: 213 funds hold $1.8 billionautomatic update · Jul 31, 2026
213 mutual funds in 2 countries hold shares of Definium Therapeutics, Inc. worth $1.8 billion, about 29.8% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 163 funds added shares and 42 sold; on balance they bought $1.0 billion. Share splits are not counted as trading.
How Definium Therapeutics, Inc. compares in Healthcare
- Market cap$5.2 B · higher than 86% of 2,013
- Price / book15.7× · lower than 8% of 1,245
- 🇺🇸 Sotera Health Company$5.2 B
- 🇺🇸 PTC Therapeutics, Inc.$5.2 B
- 🇨🇭 Galenica AG$5.2 B
- 🇺🇸 Erasca, Inc.$5.3 B
- 🇨🇭 CRISPR Therapeutics AG$5.3 B
- 🇺🇸 Veradermics, Inc$5.2 B
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Definium Therapeutics, Inc.🇺🇸 | $5.2 B | — | — | — |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Sotera Health Company$5.2 B
- PTC Therapeutics, Inc.$5.2 B
- Galenica AG$5.2 B
- Erasca, Inc.$5.3 B
- CRISPR Therapeutics AG$5.3 B
- Veradermics, Inc$5.2 B
Sources and freshness
- Market cap:
- Oct 29, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikidata, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Definium Therapeutics, Inc.? Verify and update this profile — free
Show Definium Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.